IBRX Immunitybio Inc
Company Analysis
Latest News
🔴 Immunitybio is trading 5.2% down today as wider Q2 net loss offsets strong ANKTIVA revenue growth
Immunitybio is trading 5.2% down now at $6.76 after releasing Q2 earnings that showed a wider GAAP net loss per share, primarily driven by non-cash fair value...
ImmunityBio's second quarter product revenue of $50.7M surges 92%, easily beating estimates, while net loss widens.
ImmunityBio reported second quarter 2026 net product revenue of $50.7 million, a 92% increase year-over-year, marking the eighth consecutive quarter of...
Immunitybio Inc Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
ImmunityBio is expected to report a Q2 2026 loss of $0.09 per share on revenue of $18.50 million, while the current stock price of $7.45 remains significantly...
🔴 Immunitybio is trading 4.4% down today amid broader biotech sector weakness
Immunitybio is trading at $7.12 (-4.43%) as the stock pulls back from its recent rally, tracking broader weakness across the biotechnology sector. • The...
ImmunityBio's ANKTIVA® Receives UAE Marketing Authorization for Bladder and Lung Cancer
ImmunityBio announced it has received marketing authorization from the United Arab Emirates (UAE) Emirates Drug Establishment (EDE) for its drug ANKTIVA® for...
ImmunityBio Rallies 8%, Securing Broadest Global Anktiva Approval in UAE
ImmunityBio (IBRX) shares rose nearly 8% after the United Arab Emirates (UAE) granted marketing authorization for its cancer immunotherapy, Anktiva. The...
🟢 Immunitybio is trading 4.2% up today on technical rebound and broader market strength
Immunitybio is trading 4.2% up at $7.08 on a technical rebound following several weak sessions and a sharp move higher after-hours on July 29. • The advance...
🟢 Immunitybio is trading 5.2% up today, rebounding from recent weakness without a clear catalyst
Immunitybio is trading at $7.19 (5.2% up) in pre-market, rebounding from recent weakness following a strong after-hours move on July 29. • The move appears to...
🟢 Immunitybio is trading 7.3% up today, rebounding in after-hours despite no clear catalyst
Immunitybio is trading 7.3% up at $7.33 in after-hours sessions, rebounding from recent weakness despite a lack of fresh company-specific news. • No earnings...
🔴 Immunitybio is trading 4.1% down today, underperforming a bullish biotech sector
Immunitybio is trading at $6.71 (down 4.1%), underperforming a biotech sector that is currently up over 2% on M&A-driven optimism. • The move lacks a clearly...
🔴 Immunitybio is trading 4.3% down today as shares consolidate without fresh catalysts
Immunitybio is trading at $7.08, down 4.3% today as the stock appears to be consolidating following recent volatility and a lack of new company-specific...
🔴 Immunitybio is trading 5.0% down
Immunitybio is trading at $7.66, down 5.0% from a comparison close of $8.07 during regular trading. This is a price-action follow-up, so a separate catalyst...
🟢 Immunitybio Inc is trading 4.14% up
IBRX is trading at $7.80, up 4.14%.
🟢 Immunitybio is trading 4.1% up today amid sector-wide biotech strength
Immunitybio is trading 4.1% up today at $7.75 as biotechnology stocks rally, with the sector ETF gaining 2.17%. • The move appears driven by broader sector...
🔴 Immunitybio is trading 4% down today on continued FDA warning fallout over Anktiva claims
Immunitybio is trading 4% down today at $7.42 as the company faces ongoing pressure from an FDA warning letter regarding promotional claims for its bladder...
🔴 Immunitybio is trading 4.1% down today amid FDA warning letter fallout and lawsuit risk
Immunitybio is trading 4.1% down at $7.88 as traders continue to digest the impact of an FDA warning letter regarding Anktiva promotional practices and the...
ImmunityBio Gains Institutional Backing, Sparking Retail Hopes for Anktiva Sales
Institutional investors are significantly increasing their positions in ImmunityBio. Strategic Investment Solutions boosted its stake by more than 2,300%....
🔴 Immunitybio is trading 5.8% down today in a sharp pullback without a clear catalyst
Immunitybio is trading at $8.36 (-5.75%) in a sharp pullback from its prior close of $8.87 despite a lack of major company-specific news. • No earnings...
🟢 IBRX is trading 4.7% up today on ANKTIVA optimism and positive 2026 regulatory milestones
IBRX is trading 4.7% up at $9.18 as investors continue to re-rate the stock on strong sentiment around its ANKTIVA bladder cancer therapy and positive 2026...
🔴 IBRX is trading 5.3% down today on profit-taking and broader market weakness
IBRX is trading 5.3% down at $8.44 as investors lock in profits following a period of significant gains. • The stock's recent rally was fueled by optimism...